论文部分内容阅读
本文对223例哮喘缓解期患者肺功能测定结果与正常组比较:VC、FEV_1%、MMEF、PEF、V_(75)、V_(50)、V_（25）等有非常显著降低(p<0.01),FRC、RV、RV/TLC%、CV/VC%、CC/TLC%等有非常显著增高(p<0.01),表明这些患者虽无哮喘发作症状,却仍有大小气道功能的异常,肺过度充气或/和肺气肿的存在.为此,对其中30例服用噻哌酮(ketotifen)和支气管扩张药物进行系统治疗一个月后,CV/VC%、CC/TLC%;、RV/TLC%和PEF等较治疗前有明显改善(p<0.01).而对另13例未进行系统治疗,1～3月后,VC、PEF、V_(75)、V(50)、V_(25)等较前有显著或非常显著降低(p<0.05～0.01),RV/TLC%、RV、CC/TLC%等有显著增高(p<0.05).说明对哮喘缓解期患者仍应给予继续治疗的重要性.
In this paper, 223 patients with asthma remission lung function test results compared with the normal group: VC, FEV_1%, MMEF, PEF, V 75, V 50, V 25, etc. were significantly reduced (p <0.01) , RV / TLC%, CV / VC%, CC / TLC% were significantly higher (p <0.01), indicating that these patients had no abnormalities in size and airway function even though they did not have asthma attacks. Hyperinflation, and / or emphysema.Therefore, CV / VC%, CC / TLC%; RV / TLC of 30 patients after one month of systemic treatment with ketotifen and bronchodilator (P <0.05), PEF, V_ (75), V (50), V_ (25) and P_ (25) (P <0.05 ~ 0.01), RV / TLC%, RV, CC / TLC% and so on were significantly higher (p <0.05), indicating that patients with asthma remission should continue to be treated importance.